{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:09:57Z","timestamp":1791155397763,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,3,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Matrix metalloproteinases (MMPs) are involved in tumor metastasis and are overexpressed in Kaposi's sarcoma (KS) cells. In a phase I trial of the MMP inhibitor COL-3 in patients with AIDS-related KS, the drug was well tolerated, KS regression was observed, and MMP-2 levels decreased significantly in responders compared with nonresponders. The aim of this trial was to extend these initial observations. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> This was a randomized, parallel-group, phase II study. COL-3 was administered orally once daily at one of two doses (group A received 50 mg and group B received 100 mg) to patients with AIDS-related KS. Antiretroviral therapy was permitted but not required. Serial tumor assessments and plasma levels of MMPs were obtained. Study end points were progressive KS and recurrent dose-limiting toxicity. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Seventy-five patients received COL-3: 37 in group A and 38 in group B. Fifty-seven patients (76%) had received prior KS therapy. Thirty-three patients (44%) had more than 50 KS lesions. The response rate in group A was 41%, which was significantly greater than the prespecified target rate of 20% (95% CI, 25% to 58%; P = .003); the response rate of group B was 29% (P = not significant). There were significant declines in MMP-2 and MMP-9 plasma levels from baseline to minimum value with treatment (MMP-2, P &lt; .001; MMP-9, P = .001). The most common adverse events were photosensitivity and rash. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> COL-3, when administered as 50 mg\/d, is both active and well tolerated in the treatment of AIDS-related KS. COL-3 is a promising agent for the treatment of this opportunistic neoplasm of AIDS. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.04.2614","type":"journal-article","created":{"date-parts":[[2006,3,20]],"date-time":"2006-03-20T23:58:03Z","timestamp":1142899083000},"page":"1389-1394","source":"Crossref","is-referenced-by-count":135,"title":["Randomized Phase II Trial of Matrix Metalloproteinase Inhibitor COL-3 in AIDS-Related Kaposi's Sarcoma: An AIDS Malignancy Consortium Study"],"prefix":"10.1200","volume":"24","author":[{"given":"Bruce J.","family":"Dezube","sequence":"first","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; Virginia Mason Cancer Center, Seattle, WA; School of Pharmacy, University of Maryland, Baltimore, MD; and AIDS Malignancy Consortium Operations Center, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Krown","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; Virginia Mason Cancer Center, Seattle, WA; School of Pharmacy, University of Maryland, Baltimore, MD; and AIDS Malignancy Consortium Operations Center, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; Virginia Mason Cancer Center, Seattle, WA; School of Pharmacy, University of Maryland, Baltimore, MD; and AIDS Malignancy Consortium Operations Center, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S.","family":"Bauer","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; Virginia Mason Cancer Center, Seattle, WA; School of Pharmacy, University of Maryland, Baltimore, MD; and AIDS Malignancy Consortium Operations Center, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Aboulafia","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; Virginia Mason Cancer Center, Seattle, WA; School of Pharmacy, University of Maryland, Baltimore, MD; and AIDS Malignancy Consortium Operations Center, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.12.4034"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199911000-00013"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.12.4031"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/bies.950140705"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.10.4293"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910630418"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb07072.x"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-1281(99)80031-2"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63702-9"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.12.10.2934"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1177\/08959374980120010501"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1177\/10454411910020030201"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.3.178"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10168"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006588708131"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2002.20.1.153"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1201"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200202150-00014"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.653"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200202000-00012"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.043"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.16.2003"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.956"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.04.2614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:00:35Z","timestamp":1653512435000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.04.2614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,20]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,3,20]]}},"alternative-id":["10.1200\/JCO.2005.04.2614"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.04.2614","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,20]]}}}